Positive results for Avexa
Monday, 16 March, 2009
Melbourne biotech Avexa has reported positive results from its ongoing Phase IIb trial of apricitabine (ATC) in patients with HIV.
Apricitabine is also in Phase III trials for HIV patients with resistance to common antiretrovirals. Interim results in this trial are expected shortly.
The Phase IIb trial is an open label trial for people who have failed previous HIV treatments such as 3TC. After almost two years on the trial, no resistance to ATC has been identified and no serious adverse events have been reported.
Over 85 per cent of patients have HIV loads below detectable levels and CD4 cells on average were over 500 microlitres, the company said.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
